Pacira BioSciences, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q3 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Pacira BioSciences, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q3 2019 to Q1 2024.
  • Pacira BioSciences, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $3.46M.
  • Pacira BioSciences, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $15.6M.
  • Pacira BioSciences, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$7.95M, a 173% decline from 2021.
  • Pacira BioSciences, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $10.9M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $3.46M +$10.8M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q1 2023 -$7.34M -$7.37M -25417% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 $29K -$1.72M -98.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q1 2021 $1.75M +$1.75M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q3 2020 -$125M -$125M Jul 1, 2020 Sep 30, 2020 10-Q 2020-10-30
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q3 2019 $0 Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.